The topic of this commentary hits close to home, as a patient of mine recently developed a submacular hemorrhage (SMH). This is a dreaded condition, not only because of the negative impact it can have on visual prognosis but because of its acute and unpredictable presentation in an era where remarkably effective treatments for neovascular age-related macular degeneration (AMD) otherwise exist. Anti–vascular endothelial growth factor (anti-VEGF) intravitreal injections have contributed to the growing number of patients with neovascular AMD living with excellent visual acuity (VA). But SMH can rob patients, like mine, of their vision. Thus, the quest to identify optimal treatment continues, propelled by studies like the one published by Murphy et al¹ in this issue of JAMA Ophthalmology.